The abuse of, and addiction to, d-methamphetamine (METH) interferes with many aspects of personal health, vocational performance, interpersonal relationships and financial well-being. Behavioral consequences of METH abuse and the METH trade also strain legal and emergency medical resources throughout the US. METH is therefore a significant and continuing public health concern. Current therapeutic approaches for METH addiction are less than completely effective and no approved pharmacotherapies for METH addiction exist. Recent successes in early clinical trials using immunotherapeutic approaches for cocaine and nicotine addiction have motivated interest in creating similar approaches for methamphetamine addiction. Work under the initial funding interval of this project has created the MH6 vaccine which was shown to generate antibodies which sequester METH in the blood. The vaccine also attenuated METH effects on locomotor activity, thermoregulation and intravenous self-administration of METH. New studies seek to optimize the vaccine for higher antibody titer by determining effects of different carrier proteins and adjuvants. Studies in rats will use converging models of drug-related reward, including intracranial self-stimulation reward and the dopamine response in the nucleus accumbens shell, to determine how the vaccine alters the acquisition of self- administration. Additional work will determine if an optimized vaccine can prevent the escalation to unregulated METH intake using a long-access procedure and if the vaccine can reverse an established self-administration pattern. Together these studies will make significant progress on optimizing both the design and likely translational application of an anti-METH vaccine.
Methamphetamine (METH) abuse and dependence continues to be a significant problem for personal health and well-being as well as a challenge for public health and law enforcement. Current treatment options for substance abuse have limited effect but recent vaccination strategies have shown promise. Thus the proposed studies to generate vaccines against METH have the potential to improve the treatment of METH addiction.
|Javadi-Paydar, Mehrak; Nguyen, Jacques D; Vandewater, Sophia A et al. (2018) Locomotor and reinforcing effects of pentedrone, pentylone and methylone in rats. Neuropharmacology 134:57-64|
|Aarde, Shawn M; Taffe, Michael A (2017) Predicting the Abuse Liability of Entactogen-Class, New and Emerging Psychoactive Substances via Preclinical Models of Drug Self-administration. Curr Top Behav Neurosci 32:145-164|
|Gooyit, Major; Miranda, Pedro O; Wenthur, Cody J et al. (2017) Influencing Antibody-Mediated Attenuation of Methamphetamine CNS Distribution through Vaccine Linker Design. ACS Chem Neurosci 8:468-472|
|Nguyen, Jacques D; Bremer, Paul T; Ducime, Alex et al. (2017) Active vaccination attenuates the psychostimulant effects of ?-PVP and MDPV in rats. Neuropharmacology 116:1-8|
|Nguyen, J D; Bremer, P T; Hwang, C S et al. (2017) Effective active vaccination against methamphetamine in female rats. Drug Alcohol Depend 175:179-186|
|Wenthur, Cody J; Zhou, Bin; Janda, Kim D (2017) Vaccine-driven pharmacodynamic dissection and mitigation of fenethylline psychoactivity. Nature 548:476-479|
|Collins, Karen C; Schlosburg, Joel E; Bremer, Paul T et al. (2016) Methamphetamine Vaccines: Improvement through Hapten Design. J Med Chem 59:3878-85|
|Nguyen, Jacques D; Aarde, Shawn M; Cole, Maury et al. (2016) Locomotor Stimulant and Rewarding Effects of Inhaling Methamphetamine, MDPV, and Mephedrone via Electronic Cigarette-Type Technology. Neuropsychopharmacology 41:2759-71|
|Aarde, Shawn M; Miller, Michelle L; Creehan, Kevin M et al. (2015) One day access to a running wheel reduces self-administration of D-methamphetamine, MDMA and methylone. Drug Alcohol Depend 151:151-8|
|Creehan, Kevin M; Vandewater, Sophia A; Taffe, Michael A (2015) Intravenous self-administration of mephedrone, methylone and MDMA in female rats. Neuropharmacology 92:90-7|
Showing the most recent 10 out of 23 publications